Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Adaptive Biotechnologies (Nasdaq: ADPT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management is scheduled for a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. PT / 4:50 p.m. ET. A live and archived webcast will be available in the Investors section of the company’s website. Adaptive Biotechnologies is a commercial-stage biotechnology company using its proprietary immune medicine platform to develop diagnostics and treatments across Minimal Residual Disease (MRD) and Immune Medicine business segments.

Argus Sep 2 session 1 alert

+1.29% close to close 1.2x rel. volume Open Argus

Details

News Market Reaction – ADPT

$3.93B Mkt Cap at Peak Alert

On Sep 2, the first trading day after this news, ADPT closed 1.29% above the previous close.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

Conference edition: 24th annual Fireside chat date: September 15, 2026 Fireside chat time: 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time

Conference edition

24th annual

Morgan Stanley Global Healthcare Conference

Fireside chat date

September 15, 2026

Scheduled management participation

Fireside chat time

1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time

September 15, 2026

Historical Context

5 past events · Latest: Jul 29

5 events

1. Jul 29

   2Q26 earnings

   24h Move

   +7.2%

   Revenue growth, narrowed adjusted EBITDA loss, and raised full-year MRD guidance

2. Jul 09

   Earnings date notice

   24h Move

   -3.4%

   Announcement set the date for second-quarter financial results and webcast

3. Jun 17

   Convertible notes offering

   24h Move

   -2.6%

   Upsized convertible notes offering included share repurchase and refinancing uses

4. Jun 15

   Business separation plan

   24h Move

   -1.4%

   Company announced planned separation of MRD and Immune Medicine businesses

5. Jun 15

   Convertible notes offering

   24h Move

   -1.4%

   Proposed convertible notes would fund capped calls, debt repayment, and corporate purposes

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimal residual disease

1 terms

minimal residual disease medical

"across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine."

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24^th Annual Global Healthcare Conference in New York, NY.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Adaptive Biotechnologies (ADPT) present at the Morgan Stanley 24th Annual Global Healthcare Conference in 2026?

Adaptive Biotechnologies will participate in a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time. According to Adaptive Biotechnologies, this session is part of the Morgan Stanley 24th Annual Global Healthcare Conference in New York.

How can investors access the Adaptive Biotechnologies (ADPT) webcast from the Morgan Stanley 2026 healthcare conference?

Investors can access a live and archived webcast of Adaptive Biotechnologies’ presentation via the Investors section of www.adaptivebiotech.com. According to Adaptive Biotechnologies, the webcast will cover the company’s participation in the Morgan Stanley 24th Annual Global Healthcare Conference.

What does Adaptive Biotechnologies (ADPT) do in the MRD and Immune Medicine segments?

Adaptive Biotechnologies focuses on using its immune medicine platform to support Minimal Residual Disease (MRD) testing and Immune Medicine applications. According to Adaptive Biotechnologies, these segments develop diagnostics and clinical products to diagnose, monitor, and treat diseases such as cancer and autoimmune disorders.

Is there an archived replay of Adaptive Biotechnologies’ Morgan Stanley 2026 conference presentation?

Yes. Adaptive Biotechnologies states that an archived webcast of the Morgan Stanley Global Healthcare Conference fireside chat will be available. Investors can find the replay in the Investors section of the company’s website after the live event concludes.

What is the stock symbol and exchange for Adaptive Biotechnologies participating in the 2026 Morgan Stanley conference?

Adaptive Biotechnologies trades on the Nasdaq under the stock symbol ADPT. According to Adaptive Biotechnologies, the company is a commercial-stage biotechnology firm leveraging the adaptive immune system to develop diagnostics and treatments across its MRD and Immune Medicine business segments.